ArticlebioRxiv : the preprint server for biology2026
Kaposi's Sarcoma-associated herpesvirus uses a novel protein fold to hijack RNA Polymerase II for viral late gene transcription.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Herpesviruses, including the oncogenic human pathogen Kaposi's Sarcoma-associated herpesvirus (KSHV), rely on cellular RNA Polymerase II (RNAPII) for expression of their protein-coding genes. Late in the lytic cycle, transcription initiation on a subset of KSHV genes depends on ORF24, a viral transcriptional activator that binds to viral late promoters through structural mimicry of a host transcription factor. Here, we present a structure of the N-terminal domain of ORF24, and show that it adopts a novel fold that facilitates direct binding of the RNAPII C-terminal domain (CTD). We further show that ORF24 is highly sensitive to the phosphorylation state of the RNAPII CTD, allowing for selective binding of the hypophosphorylated form to viral preinitiation complexes. By combining promoter binding and polymerase recruitment into a single protein, KSHV has streamlined essential steps in transcription complex assembly. Our work lays the groundwork for mechanistic dissection of a viral preinitiation complex.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.